Studies

The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers. Patient advocacy efforts are supported by Cancer ABCs.

Featured Studies

Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer

An International Registry for Men with Advanced Prostate Cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Our Active Study Portfolio

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase II, Randomized, 2-Arm Study of Androgen Deprivation Therapy (ADT) Plus Apalutamide And Abiraterone Acetate (AAA) versus ADT + Abiraterone Acetate (ADT + A) in Patients with High Risk Localized, Regionally Metastatic, or Low-Volume Metastatic Non-Castrate Prostate Cancers

A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with CRPC Progressing on Enzalutamide or Abiraterone

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with mCRPC and No Mutations in DNA Damage Repair

A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects with mCRPC

Single Arm Phase II Study of Abiraterone + Atezolizumab + Lupron and Stereotactic Body Radiotherapy to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours

PROMISE: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer

A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer

A Phase 1B Multiple Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration Resistant Prostate Cancer

A Phase 1/2 Feasibility, Safety, And Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects with Previously Treated Advanced Solid Tumors

Recent News +++

The PCCTC’s IRONMAN Registry Receives Prestigious PCF Challenge Award

Press Releases by PCCTC January 31, 2023

Principal Investigators Lorelei Mucci, ScD, MPH (Harvard T.H. Chan School of Public Health...

Learn More

PCCTC Medical Director Michael Morris, MD Profiled, “A Triumph Against Prostate Cancer”

Press Releases by PCCTC November 28, 2022

New technology provides a major step forward in diagnosing and treating prostate cancer.

Learn More

JUST PUBLISHED—IRONMAN: A Novel International Registry of Men with Advanced Prostate Cancer

Press Releases by PCCTC November 8, 2022

A new manuscript published in JCO Global Oncology describes the PCCTC managed IRONMAN Regi...

Learn More

The PCCTC at ASCO22

Press Releases by PCCTC June 3, 2022

More than 40,000 oncology professionals from around the world will convene at the annual A...

Learn More

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

Press Releases by PCCTC March 17, 2022

Learn More

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

Press Releases by PCCTC January 27, 2022

NORTH BILLERICA, MA, January 27, 2022 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus...

Learn More
View More News +

Follow Us

The PCCTC
@ThePCCTC
·2 d
Esteemed PCCTC investigator @Daniel_J_George (@DukeCancer @DukeGUCancer) discusses the significance of genetic muta… https://t.co/zsrwe2uhis
0
2
The PCCTC
@ThePCCTC
·3 d
The International Registry for Men With Advanced Prostate Cancer (@IRONMANregistry) is now enrolling participants a… https://t.co/Xvp4SybcU4
0
3
The PCCTC
@ThePCCTC
·4 d
RT @DrRanaMcKay: Amazing turnout at the Prostate Cancer Patient Summit. Really connecting with our community!! ⁦@UCSDHealth⁩ ⁦@UCSDCancer⁩…
7
0

Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.

Learn More